An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.
Study Details
Study Description
Brief Summary
The aim of this study is to determine the outcomes when using ertapenem for complicated urinary tract infections in the OPAt setting.
The study hypothesis: Ertapenem is an efficacious and safe therapeutic option for complicated urinary tract infections in the OPAt setting.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Enterobactericae spp. is a common cause of urinary tract infections. The prevalence of quinolone-resistance in Enterobactericae is rising and often co-exists with expression of extended-spectrum beta-lactamases (ESBL, limiting viable outpatient therapeutics options.
In Singapore, there is an increasing trend of treating patients who respond favourably to initial antimicrobial therapy in the outpatient setting (Fisher, et.al, 2006). Ertapenem is one of several agents with excellent antimicrobial activity against Enterobactericae (including ESBL producers). In view of its safety profile and its viability in elastromeric pump, it has great potential to be used in OPAT patients.
There is no study analyzing outcomes in a large cohort of patients with complicated urinary tract infections treated with ertapenem.
Study Design
Outcome Measures
Primary Outcome Measures
- Clinical Outcome [within 14 days of treatment and within 1 months after the treatment completion.]
Measured by: Clinical features within 14 days of treatmnet:(improving/resolving/deteriorating) during therapy in OPAT eg dysuria,suprapubic pain, frequency, fever, urinalysis. Clinical features of recurrences with 1 month after therapy completion Presence of hospitalization and/or Mortality
Secondary Outcome Measures
- Microbiology outcome [30 days after completion of treatment]
Measured by: urine culture results at the end of treatment and 30 days subsequent
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult patients between 21 years old to 70 years old.
-
Diagnosed with complicated urinary tract infection due to pathogen susceptible to ertapenem based on microbiology report, and the use of ertapenem is deemed clinically appropriate by the Infectious Disease physician in charge.
Exclusion Criteria:
-
Hypersensitivity reactions to Ertapenem.
-
Participation in another interventional clinical investigation within 30days
-
Unable to obtain informed consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National University Hospital | Singapore | Singapore | 119074 |
Sponsors and Collaborators
- National University Hospital, Singapore
- Merck Sharp & Dohme LLC
Investigators
- Principal Investigator: Dale A Fisher, National University Hospital, Singapore
Study Documents (Full-Text)
None provided.More Information
Publications
- Brink AJ, Richards GA, Schillack V, Kiem S, Schentag J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents. 2009 May;33(5):432-6. doi: 10.1016/j.ijantimicag.2008.10.005. Epub 2008 Dec 16.
- Fisher DA, Kurup A, Lye D, Tambyah PA, Sulaiman Z, Poon EY, Lee W, Kaur V, Lim PL. Outpatient parenteral antibiotic therapy in Singapore. Int J Antimicrob Agents. 2006 Dec;28(6):545-50. Epub 2006 Nov 13.
- Teng CP, Chen HH, Chan J, Lye DC. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections. Int J Antimicrob Agents. 2007 Oct;30(4):356-9. Epub 2007 Jul 13.
- DSRB Domain E/10/312